Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

被引：73
作者：
Tewari K.S. [1 ]
Monk B.J. [1 ]
机构：
[1] Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868-3298, 101 The City Drive
来源：
Current Oncology Reports | 2005年 / 7卷 / 6期
关键词：
Cervical Cancer; Paclitaxel; Gemcitabine; Clin Oncol; Topotecan;
D O I：
10.1007/s11912-005-0007-z
中图分类号：
学科分类号：
摘要：
Because only 16% of patients with metastatic cervical cancer are alive 5 years after diagnosis, the Gynecologic Oncology Group (GOG) has carefully designed and conducted many phase II studies to identify promising drugs. Cisplatin has emerged as the most active single agent with overall response rates of 19%. Recent phase III trials have documented response rates of 27% and 39% when cisplatin has been combined with either paclitaxel or topotecan, respectively. The comparison of cisplatin to cisplatin plus topotecan in GOG-179 has yielded the first study to show a statistically significant impact on the overall response rate, median progression-free survival, and median survival, with all outcome measures favoring the two-drug regimen. Despite these encouraging results, however, most of the responses are partial and of short duration. The need for novel combinations and the implementation of active biologic agents is implicit. The accumulated data in this disease setting, as evidenced by the experience of the GOG, are presented in this review. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：419 / 434
页数：15
相关论文
共 90 条
[1]  
Jemal A., Tiwari R.C., Murray T., Et al., Cancer statistics, 2004, CA Cancer J. Clin., 54, pp. 8-29, (2004)
[2]  
Jemal A., Muray T., Ward E., Et al., Cancer statistics, 2005, CA Cancer J. Clin., 55, pp. 10-30, (2005)
[3]  
Benedet J.L., Odicino F., Maisonneuve P., Et al., Carcinoma of the cervix uteri. 25th Annual Report on the Results of Treatment in Gynecologic Cancer, Int. J. Gynecol. Obstet., 83, pp. 41-78, (2003)
[4]  
Morris M., Eifel P.J., Lu J., Et al., Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, N. Engl. J. Med., 340, pp. 1137-1143, (1999)
[5]  
Rose P.G., Bundy B.N., Watkins E.B., Et al., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N. Engl. J. Med., 340, pp. 1144-1153, (1999)
[6]  
Keys H.M., Bundy B.N., Stehman F.B., Et al., Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N. Engl. J. Med., 340, pp. 1154-1161, (1999)
[7]  
Whitney C.W., Sause W., Bundy B.N., Et al., Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study, J. Clin. Oncol., 17, pp. 1339-1348, (1999)
[8]  
Peters III W.A., Liu P.Y., Barret II R.J., Et al., Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J. Clin. Oncol., 18, pp. 1606-1613, (2000)
[9]  
Monk B.J., Wang J., Im S., Et al., Rethinking the use of radiation and chemotherapy after radical hysterectomy: A clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial, Gynecol. Oncol., pp. 721-728, (2005)
[10]  
Thigpen T., Shingleton H., Homesley H., Et al., Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group, Cancer, 48, pp. 899-903, (1981)
123456789